5.76
+0.25(+4.54%)
Currency In USD
| Previous Close | 5.51 |
| Open | 5.51 |
| Day High | 5.77 |
| Day Low | 5.51 |
| 52-Week High | 13.93 |
| 52-Week Low | 2.86 |
| Volume | 401,049 |
| Average Volume | 692,562 |
| Market Cap | 395.33M |
| PE | -2.92 |
| EPS | -1.97 |
| Moving Average 50 Days | 4.65 |
| Moving Average 200 Days | 5.76 |
| Change | 0.25 |
If you invested $1000 in Olema Pharmaceuticals, Inc. (OLMA) since IPO date, it would be worth $117.55 as of August 18, 2025 at a share price of $5.76. Whereas If you bought $1000 worth of Olema Pharmaceuticals, Inc. (OLMA) shares 3 years ago, it would be worth $1,523.81 as of August 18, 2025 at a share price of $5.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclibOPERA-01 trial-in-progress poster to be presented on Monday, June 2 between 9:00am–12:00pm
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
GlobeNewswire Inc.
Apr 25, 2025 5:00 PM GMT
Activity in preclinical models of ovarian, prostate, and non-small cell lung cancer supports potential utility of OP-3136, a KAT6 inhibitor, in indications beyond breast cancerPatient recruitment ongoing in Phase 1 trial of OP-3136 as a monotherapy a
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
GlobeNewswire Inc.
Mar 25, 2025 8:31 PM GMT
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies